Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,235 total articles
Merck rallied more than 14% today following reports of a positive cancer vaccine readout in collaboration with Moderna. The move leaves the stock extended but supported by strong free cash flow ($16.06B), a $369B market cap and an attractive dividend yield (~2.49%). We outline a mid-term trade plan to buy a breakout, set a protective stop, and targ…
Rocket Lab's recent $397 million Space Force award changes the investment calculus. The deal, plus a $2.36 billion backlog and visible path to larger, recurring government work, reduces execution risk on top-line visibility while Neutron remains the key operational trigger. Valuation is still demanding, so this is a tactical long with defined stops…
Meta's shares are trading near the recent low after litigation headlines. The company still generates strong free cash flow ($40.98B), posts healthy returns (ROE ~26%), and trades at a ~20x P/E and ~13x EV/EBITDA. This trade idea outlines a mid-term long with a clear entry, stop, and target, while laying out the catalysts and risks that matter.
Jade Biosciences (JBIO) just delivered interim Phase 1 data suggesting an every-12-week dosing profile for JADE101 with ~70% IgA reductions. With $336M in cash, a recent $150M offering, and a market cap of roughly $1.44B, the stock offers a mid/long-term asymmetric payoff: buy near $22.71 with a stop at $18.50 and a pragmatic target of $34.00 over …
ATI is trading at premium multiples after a sustained rally driven by aerospace aftermarket strength and better aircraft production cadence. The company’s exposure to titanium, nickel-based alloys, and high-performance components gives it direct leverage to airframe build rates and defense modernization. We present a tactical long: enter at $220.00…
Hewlett Packard Enterprise has already rallied hard in 2026, but its record backlog, integrated networking push after the Juniper deal, and healthy FCF profile support another leg higher. Technicals are constructive and short interest remains material — a disciplined entry with a clear stop captures asymmetric upside while limiting risk.
Intuit's combination of tax market leadership and fast-moving AI integration creates a practical trade: buy INTU around $360 with a $420 target and a $335 stop. Strong free cash flow ($7.76B), high ROE (22%), and reasonable valuation (P/E ~21) support a long-term (180 trading days) position while the market digests legal noise and near-term tax sea…
TTM Technologies (TTMI) has become a core pick on the AI infrastructure trade. Q1 results showed revenue of $846M, up 30% year-over-year, and management raised guidance. The stock has pulled back from its 52-week high, creating a tactical long entry. I’m raising my target to reflect sustained AI-driven demand, a strategic European acquisition, and …
EyePoint plunged after a reported head-to-head miss of DURAVYU versus Eylea. The reaction looks outsized relative to the company's cash runway, the still-progressing clinical program, and heavy short positioning. We lay out a long trade with a strict stop and a long-term (46-180 trading days) horizon that targets recovery driven by trial nuance, sh…
Wendy's (WEN) is trading like a takeover candidate. With a $1.67B market cap, cheap multiples by some measures and outsized short interest, a bid led by Trian could deliver a meaningful premium. This trade idea outlines a concrete entry, stop and target for a swing trade (45 trading days) that aims to capture M&A upside while protecting against ong…
Kratos (KTOS) has shifted from a speculative technology story to a company delivering funded, production-scale defense systems. With a market cap near $11.5B, low leverage, sizable cash and a heavy backlog tied to unmanned systems and hypersonics, the equity looks actionable for a mid-term swing trade. The trade balances upside from contract conver…
SoundHound AI is a high-growth conversational AI play. Recent results show 45% YoY revenue growth and an upgraded full-year guide, but valuation is rich and the company still posts meaningful losses and cash burn. This trade idea offers a mid-term long with defined entry, target and stop to capture momentum while limiting downside if execution stum…
AppLovin (APP) has been punished despite strong revenue growth, exceptional margins and sizable free cash flow. I lay out three catalysts that could force a valuation re-rating, quantify the trade, and define precise entry, stop and target levels for a mid-term swing trade.
Shore Bancshares (SHBI) trades at a modest multiple with healthy capital metrics. Management's reported CRE portfolio average LTV below 50% and a low debt-to-equity ratio give the bank a strong cushion against localized commercial real estate stress. For risk-aware investors, a controlled long with a $23.50 entry, $21.00 stop and $28.00 target over…
GoGold (GLGDF) is trading near its 52-week highs after a steady technical run and improving volume profile. The company operates the Parral Tailings operation and holds the Los Ricos exploration complex, giving a mix of immediate cash flow and upside optionality. With a $1.25B market cap, rising moving averages, bullish MACD and active short intere…
Whitecap's increasing exposure to Veren-style assets improves realized pricing and free cash flow potential; this trade targets a mid-term re-rating tied to outperformance on volumes and margins.
Remitly (RELY) has converted scale into profitability and a rapidly growing customer base. At roughly $25.10 today and a market cap near $5.3B, the stock offers an asymmetric trade: modest valuation, accelerating fundamentals, and clear revenue-expansion levers — balanced by competitive and regulatory threats. This trade targets a $30.00 upside in …
Hermes has been sold off on cyclical concerns and short-term liquidity worries. The market is overlooking durable pricing power, direct-to-consumer control and inventory discipline that should support earnings and margins over the next 45 trading days. This trade idea lays out an actionable long with precise entry, stop and target levels and clear …
Lumentum’s revenue and adjusted EPS momentum, outsized supply commitments from hyperscalers, and a favorable technical setup make this an actionable long. I lay out entry, stop, and target levels for a mid-term swing while addressing valuation and material risks.
AstraZeneca ($AZN) is trading roughly 24% below its 52-week high and offers a reasonable entry for a mid-term swing trade. The company still generates free cash flow ($2.275B) and delivers strong ROE (16.4%), but large leverage and expensive enterprise multiples cap upside. This trade aims to capture mean reversion while protecting capital if trial…
Acadia Healthcare is expanding capacity into high-demand behavioral health segments while trading at an EV/EBITDA below 9 and a market cap of roughly $2.6B. Operational and legal headlines have pressured the stock, but a disciplined long with a clear stop can capture upside as new beds and outpatient capacity come online over the next six months.
Pagaya Technologies leverages proprietary AI to underwrite and distribute consumer and specialty credit via asset-backed securities. The company is profitable, producing positive free cash flow and trading at valuation multiples (EV/EBITDA ~8x, P/FCF ~7.2x) that leave room for upside if ABS volumes and partner flows continue to scale. This is a lon…
Cardinal Health is positioned to capture durable growth in specialty pharmaceuticals and precision medicine distribution. With a $54.66B market cap, meaningful free cash flow and a modest dividend, the stock offers a risk-reward setup for a long trade aimed at price normalization toward $270 as operational mix improves and radiopharmaceutical adopt…
Northern Oil & Gas (NOG) is offering a compelling mid-term swing trade: generous yield (~7%), low EV/EBITDA (3.1x) and analyst price targets near $48 suggest large upside from today’s $25.39. The case depends on sustained oil strength and stability in production growth; downside risk comes from negative cash flow, leverage and high short interest.
Ecovyst's sale of its Advanced Materials & Catalysts unit and the ensuing capital return/leverage reduction transform the company's risk profile. With a market cap near $1.13B, improving cash flow ($82.6M FCF) and attractive valuation metrics (EV/EBITDA ~10, EV/Sales ~1.76), the name looks set for a mid-term recovery. This trade targets a $14.00 up…
